Nilphamari

Researchers are investigating new ways to prevent leprosy by focusing on people who have been in contact with individuals infected by Mycobacterium leprae. The study evaluates the effect of a single dose or a double dose of the antibiotic rifampin given after exposure to prevent infection. It also uses a new, simple blood test called UCP-LFA to detect signs of infection early, helping to guide treatment decisions and potentially stop the spread of the disease in communities where leprosy remains common. The trial compares two dosing strategies of rifampin given to household contacts and close neighbors of newly diagnosed leprosy patients. Adults and children 5 years and older receive either a single dose or a double dose of rifampin adjusted by weight. The study uses the UCP-LFA test to measure immune markers related to M. leprae infection before and after the treatment to assess changes. This approach aims to improve early detection and prevention efforts in field settings. Participants are monitored through blood samples taken before and at 2 weeks, 4 weeks, and 6 months after receiving rifampin. These samples help track changes in immune proteins and bacterial load to evaluate the impact of the prophylactic treatment. The study involves regular follow-ups to assess effectiveness and safety, with a focus on practical, point-of-care testing methods that can be used widely in endemic areas. The total duration of participant involvement spans at least 6 months after intervention.